GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (FRA:TCE2) » Definitions » Cyclically Adjusted Book per Share

Celldex Therapeutics (FRA:TCE2) Cyclically Adjusted Book per Share : €0.00 (As of Mar. 2025)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Celldex Therapeutics's adjusted book value per share for the three months ended in Mar. 2025 was €9.797. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Celldex Therapeutics's average Cyclically Adjusted Book Growth Rate was -14.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -7.10% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Celldex Therapeutics was 6.30% per year. The lowest was -18.30% per year. And the median was -8.30% per year.

As of today (2025-05-13), Celldex Therapeutics's current stock price is €16.50. Celldex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €0.00. Celldex Therapeutics's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Celldex Therapeutics was 15.15. The lowest was 0.05. And the median was 1.16.


Celldex Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Celldex Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Cyclically Adjusted Book per Share Chart

Celldex Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.34 25.45 26.50 22.71 20.42

Celldex Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.00 22.02 19.33 20.42 -

Competitive Comparison of Celldex Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Celldex Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celldex Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=9.797/134.9266*134.9266
=9.797

Current CPI (Mar. 2025) = 134.9266.

Celldex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 46.907 100.684 62.860
201509 43.172 100.392 58.023
201512 40.480 99.792 54.732
201603 35.482 100.470 47.651
201606 31.526 101.688 41.831
201609 28.656 101.861 37.958
201612 31.321 101.863 41.488
201703 27.993 102.862 36.719
201706 24.252 103.349 31.662
201709 20.878 104.136 27.051
201712 21.628 104.011 28.057
201803 11.377 105.290 14.579
201806 10.496 106.317 13.320
201809 9.771 106.507 12.378
201812 9.119 105.998 11.608
201903 7.764 107.251 9.768
201906 6.548 108.070 8.175
201909 5.788 108.329 7.209
201912 4.986 108.420 6.205
202003 4.272 108.902 5.293
202006 5.416 108.767 6.719
202009 4.935 109.815 6.064
202012 4.345 109.897 5.335
202103 4.117 111.754 4.971
202106 3.819 114.631 4.495
202109 7.955 115.734 9.274
202112 7.944 117.630 9.112
202203 7.731 121.301 8.599
202206 7.385 125.017 7.970
202209 7.408 125.227 7.982
202212 6.524 125.222 7.030
202303 5.985 127.348 6.341
202306 5.421 128.729 5.682
202309 4.891 129.860 5.082
202312 7.042 129.419 7.342
202403 11.706 131.776 11.986
202406 11.404 132.554 11.608
202409 10.673 133.029 10.825
202412 10.748 133.157 10.891
202503 9.797 134.927 9.797

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Celldex Therapeutics  (FRA:TCE2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Celldex Therapeutics was 15.15. The lowest was 0.05. And the median was 1.16.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Celldex Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Celldex Therapeutics Headlines

No Headlines